Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F134 - What's New in Local Wound Care

Monday, February 19; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss the basics of wound bed preparation paradigm
  • Summarize new treatments available for local wound management
  • Formulate an approach to the management of chronic wounds


Wound healing starts with the treatment of the cause and patient centered concerns. A holistic approach to wound assessment is required as well as optimizing local wound care. Providing good quality local wound care requires a good knowledge of available products, their cost effectiveness and the principles for the optimal interventions. The aim of this session is to provide a review of the proper dressings, compression therapies and local wound management options for practicing dermatologists.


  • Alavi, Afsaneh, MD: AbbVie – A(H), I(Grants/Research Funding), Speaker/Faculty Education(Grants/Research Funding); Actelion – A(Fees); Asana Biosciences, LLC – I(Grants/Research Funding); Boehringer Ingelheim – I(Fees); Canadian Dermatology Association – B(NC); Celgene – SP(Fees); Dermavant Sciences – I(Fees); DS Biopharma – I(Fees); Eli Lilly and Company – I(Fees); Galderma Canada, Inc – A(H), I(Fees); Glenmark Generics Inc. – I(Fees); Incyte Corporation – I(Fees); InflaRx – I(Fees); Janssen Pharmaceuticals, Inc – A(H); LEO Laboratories Ltd (LEO Pharma) – SP(Fees); Leo Pharma Inc – I(Fees); Novartis – I(Fees); Regeneron – I(Grants/Research Funding); UCB – I(Fees); Valeant Pharmaceuticals North America LLC – A(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Almutairi, Dalal, MD: no financial relationships exist with commercial interests.
  • Dini, Valentina, MD, PhD: AbbVie – C(H); Eli Lilly and Company – C(H); KLOX TECHNOLOGIES – C(H); Mundipharma International – C(H); Novartis Pharmaceuticals Corp. – C(H);
  • Laeuchli, Severin R., MD: AbbVie – A(H); ebi-pharm ag – SP(H); Galderma Laboratories, LP – SP(H); Meda Pharmaceuticals Inc. – A(H); MiMedx Group, Inc – A(H); Urgo Group – A(H);
  • Lev-Tov, Hadar, MD: BSN Medical – I(Grants/Research Funding); DermVeda – F(SO); Factor Therapeutics – I(NC); Molynlycke – I(NC); SAWC – SP(H); TissueTech – I(NC);
  • Lowes, Michelle Anne, MBBS, PhD: AbbVie – C(Fees); Incyte Corporation – C(Fees); XBiotech – C(Fees);
  • Maibach, Howard Ira, MD: no financial relationships exist with commercial interests.
Monday, February 19
1:00 PM
Almutairi / ABCD of wound dressings
1:20 PM
Dr. Lav-Tov / Compression therapy
1:40 PM
Dini / Negative pressure wound therapy and new generations
2:00 PM
Dr. Lowes / Local management of HS
2:20 PM
Dr. Laeuchli / Scar management
2:40 PM
Dr. Maibach / Contact dermatitis to wound products
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 32B
  • CME Credits
  • Type
  • Afsaneh Alavi, MD, FAAD
  • Dalal Almutairi, MD
  • Hadar Lev-Tov, MD, FAAD
  • Howard Ira Maibach, MD, FAAD
  • Michelle Anne Lowes, MBBS, PhD
  • Severin R. Laeuchli, MD
  • Valentina Dini, MD, PhD